The company is focusing on autologous esophageal regenerating epithelial sheets for wounds after esophageal cancer resection endoscopic surgery (ESD). Esophageal regenerating epithelial sheets are grown from cells collected from the oral mucosa of a patient, prepared as a cell sheet using a thermoresponsive culture dish, and transplanted to the esophageal ulcer surface after ESD. They will apply for approval in the first half of 2019 and hope to obtain approval in 2019.

Nikkei Biotech news release, August 27, 2018